Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Immune Network Research ( IMM-V ) -- Ignore unavailable to you. Want to Upgrade?

To: John Fairchild who wrote (54)	9/23/1998 3:17:00 PM
From: John Fairchild	Read Replies (1) \| Respond to of 57

Immune Network Research Ltd - Phase II primate study nearing completion Immune Network Research Ltd IMMShares issued 19,970,4521998-09-22 close $0.17Wednesday Sep 23 1998Mr. Victor Jones reports The phase II primate study of the company's proprietary monoclonal antibody 1F7 on the immune systems of SHIV infected and control primates is nearing completion and now includes a second series of injections of mAb 1F7. The encouraging condition of the primates during the six month study of mAb 1F7 has allowed the study to be expanded to model repeated administration of mAb 1F7. Analysis of viral levels during the entire study is scheduled and will provide predictive information, as it is a recognized model of HIV disease in humans. The next milestone is the application for the human trial of mAb 1F7 under an investigational new drug protocol. Data from the six month primate study will be used to evaluate whether using mAb 1F7 to strengthen the immune system response to HIV infection lowers plasma virus load. In an earlier study, beneficial effects on the immune system of SHIV infected macaques were reported and mAb 1F7 normalized the immune response against the viral infection in the monkeys. Results from the current study will also assist with defining the selection criteria for the human IND trial of mAb 1F7. The private placement announced earlier has closed with subscriptions for 400,000 units priced at 20 cents per unit for a total of $80,000. In response to increased investor interest, Peter Laipnieks has been appointed director - investor relations for the company. The board of directors has granted Mr. Laipnieks an option to purchase 150,000 shares at 15 cents for five years. The board has also approved the transfer of 500,000 escrow shares between a director and an officer. In addition, Alliance Corporate Services, a Victoria based investor relations group, has been retained to assist with investor relations activities as the company looks towards reporting study results and financing clinical trials. (c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com old url (better for printing)